about
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.Relationship between microRNA-146a expression and plasma renalase levels in hemodialyzed patients.Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung CancerThe application of real-time PCR technique to detect rare cell clones with primary T790M Substitution of EGFR gene in metastases of non-small cell lung cancer to central nervous system in chemotherapy naive patients.Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancerPolymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.Impact of I/D polymorphism of ACE gene on risk of development and course of chronic obstructive pulmonary diseaseMechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system.The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings.The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma.Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report.Analysis of primary-miRNA-3662 and its mature form may improve detection of the lung adenocarcinoma.Polymorphism of Promoter Region of TNFRSF1A Gene (-610 T > G) as a Novel Predictive Factor for Radiotherapy Induced Oral Mucositis in HNC Patients.Role of circulating microRNA in hemodialyzed patients.Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer.Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.Rare co-existence of mutation in KRAS and ALK gene re-arrangement in an adenocarcinoma patient--a case report.Letter to the editor concerning first-line therapy with afatinib - an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations.EGFR gene mutations in patients with adenosquamous lung carcinoma.The diagnostic role of plasma circulating precursors of miRNA-944 and miRNA-3662 for non-small cell lung cancer detection.Analysis of RTEL1 and PCDHGB6 promoter methylation in circulating-free DNA of lung cancer patients using liquid biopsy: A pilot study.Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer.Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.Investigation of relationship between precursor of miRNA-944 and its mature form in lung squamous-cell carcinoma - the diagnostic value.Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.Cytology smears as diagnostic material for EGFR gene testing in non-small cell lung cancer.Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patients.Is microRNA-31 a key regulator of breast tumorigenesis?miRNA-130a Significantly Improves Accuracy of SGA Nutritional Assessment Tool in Prediction of Malnutrition and Cachexia in Radiotherapy-Treated Head and Neck Cancer Patients.Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patientsRelationship between TNF-α -1031T/C gene polymorphism, plasma level of TNF-α, and risk of cachexia in head and neck cancer patientsPredictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and GemcitabineDetection, prediction, and prognosis: blood circulating microRNA as novel molecular markers of head and neck cancer patientsCombined analysis of miRNA-181a with phase angle derived from bioelectrical impedance predicts radiotherapy-induced changes in body composition and survival of male patients with head and neck cancer
P50
Q33751194-57BCD4BD-FA1D-4072-AA6A-A24A00352C8FQ33797472-DD24619E-3E09-4C0B-9BB0-70B46872C542Q33844457-1704F2EA-26A7-485E-B301-6C1E44D32791Q34253217-8BBC40A7-9D6A-43AF-8B1E-65A2F160AFEDQ34271013-219E0613-ADBA-4B5A-817D-1EF8464577DBQ34491507-4724B673-649A-4A26-AB46-6C9CF3EEF611Q34809526-5800A311-EA3C-48FF-80EE-1EF37BFF418DQ35700740-ECD58518-60A7-4756-96EC-1C380536E0E2Q35967971-F130BDE3-28F2-4648-B894-0730447A53EDQ36378565-4EFF59BC-BE3B-4881-9CC1-6A033F10FA11Q36845267-E4C34BF9-D0AB-4C13-A7E2-55EB0D43BC64Q36942619-BD0FBFE5-09F7-4F76-87A8-3C5588DE74CBQ37198266-32556AD2-6654-4B1B-B50B-F964A4A1E22AQ37229404-AECC73D1-E0CC-4382-9EC3-FB02715773F2Q37412625-9964BFA6-5E7E-460A-ABF1-77065D08835BQ37470875-5B12D957-B38A-4990-BB50-E9BB0EBC5D09Q37677042-2F427B81-0257-428B-B8A0-DC46952A13C8Q38766106-F7CFB533-5979-4BB5-AA42-0ABD17C3C9E0Q38841171-9CA11FAC-616C-4BA5-8FE4-FE871043552DQ39149319-D896DF4F-C78C-458A-A537-3CEDAAB54FD8Q41030204-19178C13-898D-4724-9CBC-21CF0F4E09CAQ41608748-3C500CA5-9565-498C-95C4-4825DF58BD3CQ42208981-FAE62E67-0BD2-4F61-B8D2-5347ADE27E0CQ43190679-BC8D2828-9486-40BC-B497-4D639BC37120Q44690866-2A3AC1C0-813D-4A86-9557-AFF4E8B798D4Q47757715-FB9E5AA4-CCD7-412E-AFB0-06FE8F62A7F5Q51477838-DDA4F5E3-90EE-4AD1-A06D-8755BD49ECEEQ51597823-A0BD3354-4CEE-43D3-BE55-F2F1666F2173Q51600504-87CCDB99-0B11-4E5E-AEB0-549E0EB241CDQ52678647-593A1015-692A-47EF-B0B9-26C5AE44300AQ53466708-D836F5CD-CF25-4240-9659-AAF81008F751Q54263491-0D409A6A-353D-4D0F-B0DE-4BD02D5DC0F5Q55036457-1CD1036A-B12B-4DC0-B73F-D050683D82A7Q55129896-EDAC65AA-BD98-4632-95F0-5FFED26284E4Q64883986-F6705987-268B-4E34-965C-2ABBD54875F4Q85359341-8D78012F-E9A9-4135-BBF5-1BEBB58FC5F7Q88868076-36650629-3843-4B56-8905-85F21B69275EQ90679194-FA8EB952-2736-4C7F-94EF-7A07FFA0C76FQ91506483-9E64DFE0-5892-4AE3-83F6-E6310FCED318Q92530719-41AEF7F2-72DF-4027-B76F-4BA8214421C7
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-9174-8548
@en
name
Tomasz Powrózek
@ast
Tomasz Powrózek
@en
Tomasz Powrózek
@es
Tomasz Powrózek
@nl
type
label
Tomasz Powrózek
@ast
Tomasz Powrózek
@en
Tomasz Powrózek
@es
Tomasz Powrózek
@nl
prefLabel
Tomasz Powrózek
@ast
Tomasz Powrózek
@en
Tomasz Powrózek
@es
Tomasz Powrózek
@nl
P106
P1153
55505007600
P31
P496
0000-0001-9174-8548